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ABSTRACT
Objectives In this study, we sought to evaluate the extent 
of further visual field that could be assessed when using 
stimulus size V in standard automated perimetry compared 
with size III in advanced stage glaucoma and whether cut- 
off values could be determined for when to switch from 
size III to size V.
Design Prospective cross- sectional study.
Setting Single- centre outpatient eye clinic in India (New 
Delhi).
Participants Advanced stage glaucoma defined as stages 
3–4.
Intervention Central static perimetry with Octopus 900 
G programme (size III stimulus dynamic strategy) and 
low vision central programme (size V stimulus dynamic 
strategy).
Primary and secondary outcome measures Visual field 
assessment for right and left eyes with both sizes III and V 
were undertaken within one clinic visit.
Results We recruited 126 patients (170 eyes). Mean 
patient age at assessment was 55.86 years (SD 15.15). 
Means (SD) for size III versus size V, respectively, were 
6.94 dB (5.58) and 12.98 dB (7.77) for mean sensitivity, 
20.02 dB (5.67) and 19.22 dB (7.74) for mean deviation, 
5.89 dB (2.29) and 7.69 dB (2.78) for standard loss 
variance and 3.32 min (1.07) and 6.40 min (1.43) for test 
duration. All except mean deviation were significantly 
different between size III and V tests.
Conclusion Useful visual field information was obtained 
with size V stimuli which allowed continued monitoring of 
these patients that was not possible with size III. Increased 
test duration, standard loss variance and mean sensitivity 
were found with size V, as expected, given that more visual 
responses were obtained with the increased target size. 
A switch from size III to V may be considered when mean 
sensitivity reaches 10 dB and/or mean deviation reaches 
18 dB.
INTRODUCTION
Standard automated perimetry using stim-
ulus size III is an internationally accepted 
visual field assessment for glaucoma.1 Static 
threshold perimetry is particularly adept in 
aiding detection of early visual field loss in 
glaucoma. For patients with glaucoma, the 
usual choice of visual field assessment is static 
perimetry using a threshold strategy to assess 
the central 24°–30° of the visual field of right 
and left eyes individually.1 In clinical prac-
tice, a number of issues can arise with these 
central assessment programmes. As glaucoma 
progresses and the central visual field dete-
riorates to the extent that minimal (if any) 
visual field remains, appropriate and reliable 
evaluation can become difficult.
For patients with severe to advanced stage 
disease, central visual field assessment can 
show substantial visual field loss and, there-
fore, is limited in providing useful informa-
tion about further progression or stability of 
the visual field loss, or for providing infor-
mation about the individual’s functional 
visual status. In these patients, further anal-
ysis options for visual field assessment must 
be considered. Where the central visual field 
island remains, it is possible to target assess-
ment to the central 10 degrees of visual 
field. Tomairek et al2 showed a consider-
able number of eyes with severe glaucoma 
with absolute visual field defects on 24–2 
programme testing showing relative defects 
involving only some points of the central 10° 
on the 10–2 programme. Thus, they stressed 
the importance of detailed central testing to 
underpin intensive treatment to preserve the 
residual central visual field.
A further alternative is to continue assess-
ment of the central 30° but to increase the 
Strengths and limitations of this study
 ► Size V stimulus in standard automated perimetry 
has a greater dynamic range than size III stimulus.
 ► Visual field results of advanced stages 3–4 glauco-
ma meeting reliability criteria were analysed.
 ► Sample size calculations were met for recruitment 
to this study.
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stimulus to size V.3–5 While there is considerable debate 
over the use of different stimulus sizes in automated 
perimetry,6–10 from a clinical perspective, size III remains 
the standard stimulus in mainstream clinical use.1 7 
However, when visual field results using standard auto-
mated perimetry show severe loss, use of size V stimulus 
becomes a consideration.
There are conflicting reports of size V vs III in early 
visual field loss. The use of the larger stimulus size could 
prevent the detection of small localised defects because 
the large stimulus size stimulates not only the area of 
visual field loss but also the surrounding, better, areas 
of visual field.6 However, Wall et al5 found that when 
the data were binned by mean deviation, size V main-
tained its advantage to detect visual loss even in the bin 
with the best mean deviation. Further, Flanagan et al11 
reported that while size III testing resulted in a greater 
depth of the defect, size V, because of its better retest 
variability, flagged abnormal test locations in early glau-
coma at least as well as size III. This is not directly rele-
vant to studies that focus specifically on severe visual 
field loss. With severe visual field loss, when using size 
III, it is not possible to gather reliable visual field data by 
increasing stimulus contrast (ie, lower decibel values) as 
often there is no response within damaged areas of visual 
field.6 7 Thus, a further option is to increase the target 
size instead.
The useful dynamic range of perimetry is the range of 
disease severities over which useful measurements can be 
obtained. With increasing visual field loss, the response 
within the area of visual field loss becomes more variable 
because of decreased retinal ganglion cell response rate 
along with the limited number of stimulus presentations 
in each location of the test programme.6 7 Use of size V 
stimulus has been shown to have a greater dynamic range 
and a similar number of abnormal test locations when 
compared with the traditionally used size III stimulus.3 
Higher sensitivity is achieved at the same location giving 
more reliable and less variable estimates of sensitivity at 
the damaged visual field locations. Gardiner et al reported 
that for rapidly progressing eyes, use of size V could repre-
sent more than 5 years of added, useful and reliable test 
results. For less rapid loss, size V could provide many years 
of reliable clinical information.6
In this study, we aimed, in a pragmatic clinical study, to 
investigate the information obtained from central static 
visual field assessment comparing size V vs size III targets 
using the Octopus 900 G and low vision central (LVC) 
programmes in patients with advanced stage glaucoma. 
We hypothesise that, for many patients, we would obtain 
useful visual field results with size V to use as a new base-
line for visual field status for subsequent comparison over 
follow- up, and further, comparative data of size III and V 
could be used to provide a recommendation for transfer 
from one test strategy to the other.
MATERIALS AND METHODS
Design
We undertook a prospective, comparative, observational 
cross- sectional study in a single centre in New Delhi, India. 
We followed the Strengthening the Reporting of Obser-
vational Studies in Epidemiology checklist for reporting 
cross- sectional studies.
Recruitment
The study recruited patients with visual field loss due to 
advanced glaucoma and who met our inclusion criteria. 
Consecutive patients with an existent clinical diagnosis 
of glaucoma requiring visual fields were recruited from 
ophthalmology outpatient clinics between 2016 and 2017. 
Severe glaucoma was diagnosed according to the Interna-
tional Classification of Diseases (ICD) diagnostic code 9 
(365.73) and 10 (7th digit ‘3’). Diagnostic code 365.73 
represents the glaucoma stage code for severe, advanced 
and end- stage glaucoma consisting of ‘glaucomatous 
visual field abnormalities in both hemifields and/or loss 
within 5° of fixation in at least one hemifield’.12 13 ICD 
version 9 codes were updated in 2015 to version 10 codes 
which consist of seven digits.14 The first three indicate 
the code category and the last four provide added detail. 
Where the last digit is ‘3’, this indicates severe glaucoma 
regardless of the type or cause of glaucoma. For example, 
H4010×3 represents unspecified open angle severe stage 
glaucoma.
Inclusion criteria
We included adult patients attending for visual field assess-
ment with a diagnosis of severe or advanced glaucoma 
(stages 3–4), sufficient motor ability to sit at the perimeter 
unaided, ability to press the response button, sufficient 
cognitive ability to understand and follow instructions for 
performing the test, and willingness to undergo standard 
visual field assessments on the same day.
Exclusion criteria
We excluded patients with a diagnosis of stages 1–2 glau-
coma, visual acuity worse than 1.0 logMAR (logarithm of 
the Minimal Angle of Resolution), those unable to sit at 
the perimeter, those with unreliable visual fields, unable 
to follow instructions for performing the test or too ill to 
complete the full assessment.
Patient and public involvement
This study addresses a top research priority identified by 
patients and the public in a national (UK) consultation 
process: ‘what is the most effective way of monitoring the 
progression of glaucoma?’ (https://www. jla. nihr. ac. uk/). 
Patients were not involved directly in the design and 
conception of this study.
Visual field assessment
Past studies have frequently used the 24–2 programme 
when testing visual fields in advanced glaucoma.3–5 
The Octopus 900 perimeter (Haag Streit AG, Bern, 
Switzerland) G programme (dynamic strategy) has a 
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physiology- based grid of 59 test locations within the central 
30°.15 Locations are clustered more closely together 
centrally (2.8° spacing) with five central foveal locations 
and 17 test locations in the macular region. Locations are 
spaced further apart peripherally with emphasis on loca-
tions in nasal step regions and with more test locations 
nasally than temporally. There is no weighted analysis of 
test locations. Test locations are distributed in a pattern to 
follow retinal nerve fibre bundles to facilitate the detec-
tion of glaucomatous visual field loss. The Octopus 900 
perimeter LVC programme (dynamic strategy) has a grid 
of 75 test locations within the central 30°.15 One location 
is within the central fixation area and the remaining 74 
locations are spaced equally apart by 6° with an off- set 
from the horizontal and vertical meridians of 2°. Static 
visual field results were deemed unreliable if combined 
false negative and false positive responses exceeded 25%.
The study protocol consisted of visual field assessment 
with static G Octopus 900 perimetry using size III and 
static LVC size V targets (two tests per eye) on the same 
day. The order of assessment was randomised for size III 
vs size V. The G and LVC programmes were run as stan-
dard with the size III target size (0.43° in diameter) or 
with the size V target size (1.72° in diameter).
Sample size
We studied two main outcomes: mean sensitivity and 
mean deviation.
For mean sensitivity sample size, we assumed a differ-
ence of 3 dB to be of clinical importance. Wall et al5 
reported lower and upper quartiles of 17.4 dB and 24.5 dB 
which are equivalent to an SD of 3.55. Based on these 
figures, with pairwise t- test, significance level of 2.5% and 
power of 85%, this leads to a sample size of 15 eyes (1 eye 
per patient).
For mean deviation, in the sample size we assume a 
difference of 10% decrease to be clinically relevant. Wall et 
al4 showed a 15% decrease in their patients, while pooled 
SD was 5.5 dB.7 With pairwise t- test, and significance level 
of 2.5%, and power of 85%, this leads to a sample size of 
126 eyes (1 eye per patient).
Statistical analysis
A direct comparison of results was made for static results 
using the statistical package SPSS V.25 (IBM SPSS Statis-
tics). The unit of analysis was per eye.16
Glaucoma typically affects both eyes, thus, each eye is 
not considered independent when considering analysis of 
visual field assessments. Assessments are usually reported 
for worst affected eye only. In this study, we sought to eval-
uate visual field data available from size V vs size III perim-
etry. We had all the data from both eyes for many patients, 
hence we aimed to use all the data from all eyes as our 
primary analysis. For the purposes of sensitivity analysis, 
we also present results from worst eyes only.16 We chose to 
include worst eyes only for this analysis on the basis that 
we wished to determine at what point within worst fields 
we should transfer from size III to size V testing. Worst eye 
was defined as the eye with greater mean deviation value 
on G1 static perimetry.
To evaluate normality of distribution of results from 
right and left eyes, a Kolmogorov- Smirnov test was used. 
Further we conducted a general linear model analysis for 
difference between eyes in mean sensitivity and mean 
deviation. For this model, the difference in mean sensi-
tivity, or mean deviation, value was the dependent vari-
able and the eye (right vs left nested within the patient) 
was treated as random factor. We also did analysis of the 
visual field measurement difference in the worse eye via a 
paired t- test with Bonferroni adjustment for mean sensi-
tivity and mean deviation calculations.
To compare the results of the G programme when 
undertaken with size III and size V targets, variation was 
evaluated for:
 ► Mean sensitivity.
 ► Mean deviation.
 ► Standard loss variance.
We further compared mean sensitivity and mean devi-
ation values for each of the four quadrants of the visual 
field to determine if different quadrants showed compa-
rable changes. Quadrants were defined as Q1 (supe-
rior nasal field), Q2 inferior nasal field), Q3 (superior 
temporal field) and Q4 (inferior temporal field) for both 
right and left visual field results. Duration of assessments 
was also compared.
Scatterplots include linear regression lines and locally 
estimated scatterplot smoothing (loess) curves. The 
linear regression line assesses strength of linear associa-
tion between two continuous variables with r2=0.0 indi-
cating lack of linear association (ie, lack of correlation). 
Correlation is first assessed by its p value (p) and then, 
if significant, the correlation is judged as none, small, 
medium or large if r2 is 0–0.01, 0.01–0.09, 0.09–0.25 or 
more than 0.25.17 18 A non- directional p value, that is, 
two- sided alternative hypothesis, is used. The value of r2 
tells us how much variability is shared between variables. 
The loess curve is a local non- linear regression curve in 
which the fitting of each point is weighted towards the 
data nearest to that point. It makes no assumption about 
the association between variables and is used to visually 
observe the possible nature of the association between 
two continuous variables. It can be used as a model-
ling tool and provides a nonparametric regression that 
focuses on the fitted curve.19 The fitted points and related 
standard errors do respect a particular estimate but are 
estimated to the whole curve.20 The default span was set 
to values ranging from 0.60 to 0.80 as a trade- off to ensure 
sufficient data for an accurate fit in order to reduce vari-
ance, and to avoid an oversmoothed regression in order 
to reduce bias. Along the loess curve, the cross- section 
between the x and y axis relating to the main point of 
inflection along the curve was used to indicate cut- off 
values between data represented along the x and y axes, 
and therefore, for this study, used to calculate potential 
cut- off values for transfer of testing from size III to size 
V stimulus. The inflection point was taken to indicate at 
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what value the relationship between III and V was possibly 
changing (as relevant when the linear relationship does 
not explain the association between III and V). The point 
of greatest curvature is suggested as a potential point of 
transitioning from size III to V as that is the point when 
the size III stimulus accelerates in its inability to detect 
change in visual field—relatively when compared with 
size V test. We report the inflection point as a range of 
values, as observed for the range of (α) 0.60–0.80.
In this paper, all global indices are reported as positive 
numerical values, including mean sensitivity, mean devia-
tion and standard loss variance.
RESULTS
Primary analysis: all patients/eyes
Results are presented for 126 patients (170 eyes) with reli-
able visual field performance; 29 eyes at stage 3 and 141 
at stage 4. A further 46 eyes were excluded because of 
unreliable visual field performance or visual field results 
graded at stage 2 or better. The worst affected eye was 
right in 64 (50.8%) and left in 62 (49.2%). Mean age 
at time of testing was 55.86 years (SD 15.15; 58 (range 
13–83)). Figure 1 displays one example of size III vs size V 
results for one patient.
Distribution of data
Visual field assessment data was tested to be normally 
distributed (Kolmogorov- Smirnov test). Further, general 
linear model analysis with random effect being the subject 
and fixed effect being (1) eye laterality (right vs left 
eye) or (2) worst versus better eye, with respect to mean 
sensitivity, showed no significant difference between size 
V versus size III data (p=0.888 and p=0.644 respectively).
Size III versus size V differences
Results are outlined in table 1 for differences, and signif-
icance, for mean sensitivity, mean deviation and standard 
loss variance, along with differences across quadrants plus 
test duration. Differences for mean sensitivity between 
sizes III and V were about 6 dB overall (higher values for 
size V) and 5–7 dB across quadrants with greatest increases 
in inferior quadrants. A strong linear relationship and 
large correlation was found between mean sensitivity for 
size III and V stimuli (figure 2: r2=0.731, p=0.0001). Using 
the loess curve to consider differences between size III 
and V stimuli, the point of greatest inflection (visualised 
on the scatterplot with value taken from y axis) is approx-
imately 4–6 dB for size III stimulus.
Global mean deviation was significantly lower for size 
V but not clinically significant with significant differences 
only in inferior quadrants. A strong linear relationship 
and large correlation was found between mean deviation 
for size III and V stimuli (figure 2: r2=0.735, p=0.0001). 
Using the loess curve to consider differences between size 
III and V stimuli, the point of greatest inflection is approx-
imately 22–24 dB for size III stimulus. Diffuse defect was 
lower and standard loss variance was higher for size V 
(see online supplemental figure 1) representing more 
visual field responses with the size V target. Test duration 
increased for size V but was likely due to more patient 
responses being obtained due to presence of more visible 
targets.
Figure 1 Illustrative results of static size III versus size V perimetry. (A) G1 static perimetry with size III, left eye. (B) LVC static 
perimetry with size V, left eye. Static perimetry (using size III) results show a severely restricted visual field while static perimetry 
(using size V) results display better temporal visual field and inferonasal visual field. LVC, low vision central; MD, mean deviation; 
MS, mean sensitivity; IOP, intra ocular pressure; OS, left eye; RF, reliability factor; VA, visual acuity.
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Sensitivity analysis: worst eyes only
Taking only the worst eye for each patient, results are 
presented for 126 patients (126 eyes) with 18 eyes at stage 
3 and 108 at stage 4. The worst eye was right in 64 (50.8%) 
and left in 62 (49.2%).
Size III versus size V differences
Results are outlined in table 2 for differences, and signif-
icance, for mean sensitivity, mean deviation and standard 
loss variance, along with differences across quadrants plus 
test duration. Differences for mean sensitivity between size 
III and V were about 6 dB overall (higher values for size 
V) and 5–7 dB across quadrants with greatest increases in 
inferior quadrants. A strong linear relationship and large 
correlation was found between mean sensitivity for size 
III and V stimuli (figure 3: r2=0.678, p=0.0001). Using the 
loess curve to consider differences between size III and V 
stimuli, the point of greatest inflection (visualised on the 
scatterplot with value taken from y axis) is approximately 
3–5 dB for size III stimulus.
Global mean deviation was significantly lower for size 
V but not clinically significant (figure 3) with significant 
differences only in inferior quadrants. A strong linear 
relationship and large correlation was found between 
mean deviation for size III and V stimuli (figure 3: 
r2=0.687, p=0.0001). Using the loess curve to consider 
differences between size III and V stimuli, the point of 
greatest inflection is approximately 22–24 dB for size 
III stimulus. Diffuse defect was lower and standard loss 
variance was higher for size V (see online supplemental 
figure 2) representing more visual field responses. Test 
duration increased for size V but was likely due to more 
patient responses being obtained due to presence of 
more visible targets.
DISCUSSION
Detection of visual field loss in glaucoma and other 
optic neuropathies is well reported with discussion of 
early detection methods, exploring visual field defects 
with steep border slopes and for conversion of disease/
progression.1 21 Studies have mostly used the 24–2 central 
static threshold programme.3–5 In this study, we sought to 
explore the use of size V versus size III targets using the 
Octopus 900 G and LVC programmes to evaluate detec-
tion of absolute versus relative visual field loss in advanced 
(stages 3–4) glaucoma. This was a pragmatic clinical study 
in which we primarily wished to evaluate how much addi-
tional useful information could be obtained from a switch 
to stimulus size V at a stage of moderate to severe glau-
coma when visual field results had reached a level of loss 
with stimulus size III, such that meaningful information 
could no longer be extracted from the results to guide 
clinical decision making.
One recent study sought to gather patient perspectives 
and reliability based on clinical grounds while comparing 
size III and V stimulus sizes using a 24–2 test programme.22 
They concluded that adjustment of testing to use of size 
V increased their patient cooperation and was a valid 
option when attempting to gather more reliable perim-
etry results. From our clinical perspective, we found the 
results using size V to provide more visual field data to 
help inform clinical decision making and a grounding 
towards future disease monitoring.
The mean sensitivity provides a single global indicator 
value for the overall visual field sensitivity. We found the 
mean sensitivity value to increase overall by about 6 dB 
for size V versus size III but with a difference of about 
10 dB (in keeping with that expected by the change in 
Table 1 Differences in visual field parameters for target size—all eyes
G1, size III G1, size V Difference








MS 6.94 5.58 12.98 7.77 −6.04 4.18 0.0001 0.005 0.0002
MD 20.04 5.67 19.22 7.74 0.82 4.15 0.023 0.007 0.046
SLV 5.89 2.29 7.69 2.78 −1.80 2.60 0.0001 0.0001 *
DD 17.13 7.86 14.76 9.47 2.37 5.46 0.0001 0.009 *
MS Q1 5.31 5.48 10.48 8.78 −5.17 5.21 0.0001 0.0001 *
MS Q2 7.70 7.48 14.40 9.74 −6.70 5.33 0.0001 0.004 *
MS Q3 6.27 5.78 12.05 8.68 −5.77 5.42 0.0001 0.114 *
MSQ4 8.23 7.59 14.68 10.12 −6.45 5.37 0.0001 0.005 *
MD Q1 21.29 5.55 21.13 8.70 0.16 5.16 0.662 0.001 *
MD Q2 19.59 7.58 18.28 9.77 1.31 5.31 0.010 0.005 *
MD Q3 20.25 5.86 19.58 8.60 0.67 5.37 0.119 0.123 *
MD Q4 19.06 7.61 18.00 10.08 1.06 5.37 0.018 0.006 *
Duration 3.32 1.07 6.40 1.43 −3.07 1.66 0.0001 0.015 *
Q1 (superior nasal field); Q2 inferior nasal field); Q3 (superior temporal field); Q4 (inferior temporal field).
*Not corrected as study not powered for these comparisons.
MS, mean sensitivity; MD, mean deviation; SLV, standard loss variance; DD, diffuse defect.
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stimulus size) at mean sensitivities of 10–30 dB. This indi-
cates less visual field loss for size V stimulus compared 
with the indication of absolute defects for size III stim-
ulus when mean sensitivity values are low (<10 dB) and 
is indicative of the relationship between stimulus size 
and luminance.22 Many perimeter parameters are such 
that at maximum luminance, the size III target has a 
calibrated range of 2–44 dB and the size V target has a 
range of 10–54 dB (10 dB difference). As expected, the 
larger stimulus size increases sensitivity and this is partic-
ularly so at greater eccentricities.6 In clinical studies, this 
is shown as the effective dynamic range of size V being 
about one log unit greater than size III.3 Gardiner et al 
confirmed size V resulted in higher sensitivity at the same 
location, providing more reliable and less variable esti-
mates of sensitivity in damaged visual fields. Their higher 
sensitivity was on average 5.6 dB—similar to our average 
of 6 dB and to the average of 6 and 7.6 dB reported by 
Morgan et al22 and Choplin et al,8 respectively.
The mean deviation provides a single global indicator 
value for the overall visual field sensitivity in comparison 
to an age- matched normal visual field. We found a slight 
but clinically insignificant reduction in mean deviation 
for size V vs III. The association between size III and V 
targets has been reported as approximately linear to a 
sensitivity of about 20 dB. Size V had a greater effective 
dynamic range with eight discriminable steps for progres-
sion—about twice as many as with size III.23
A second objective of our study was to consider indica-
tion levels for a transfer from size III to size V for static 
perimetry. In our analysis, we used the loess curve to 
compare differences between size III and V stimuli. The 
loess curve does not provide confidence values. We found 
the point of inflection to be within an overall range of 
approximately 4–6 dB for size III stimulus on mean sensi-
tivity and 22–24 dB on mean deviation. Arguably, the 
inflection point might be considered the latest point at 
which to switch from size II to size V. A more sensible 
approach would be to switch before severe damage to the 
visual field occurs to allow progression to be more reli-
ably tracked with size V over, potentially, a longer period 
of time. We therefore provide a clinical recommendation 
that at a mean sensitivity level of 10 dB (4 dB above the 
higher inflection estimate) and/or at a mean deviation 
level of 18 dB (4 dB below the lower inflection estimate) 
on a visual field using size III, a switch may be made to 
using size V stimuli for subsequent visual field assessment.
Mean deviation reduced more for inferior visual field 
quadrants. Our discrepancy between superior and infe-
rior visual field cannot be explained by the number of test 
locations as test location numbers are equal for the supe-
rior and inferior visual field. The greater reduction in 
mean deviation for inferior visual field may be explained 
by the presence of better inferior visual field compared 
with the extent of superior visual field loss. In both 
primary open and closed angle glaucoma, visual field 
damage has often been reported as being more severe in 
the superior visual field than inferiorly.24
Variability for size V targets has been reported as being 
substantially lower than for size III.3 However, in later 
studies, Wall and colleagues4 5 did not find a significant 
reduction in size V variability compared with size III. This 
was partly explained by the use of size V allowing patients 
to detect more targets than with the smaller size III—0 
dB responses using size III become detectable decibel 
responses with size V. Thus, as patients can see more, the 
extra responses add to variability. This was not apparent 
in cases with most severe visual field loss with mean sensi-
tivities close to 0 dB but emerged from a mean sensitivity 
Figure 2 Mean sensitivity and mean deviation 
comparisons—primary analysis of all eyes. (A) Mean 
sensitivity. Straight line is the linear regression line; curved 
line is the loess regression curve. Comparisons generally 
show clustering where mean sensitivity is close to 0 dB, 
that is, worst visual field. There is a ‘floor’ effect with size 
III, yielding many zeros, while size V gives, for most, larger 
values. The linear regression line and loess regression curve 
show large correlation for size V (r2=0.731, p<0.0001). The 
loess point of inflection (value taken from the y axis) is 
approximately 4–6 dB. (B) Mean deviation. Straight line is 
the linear regression line; curved line is the loess regression 
curve. The linear regression line and loess regression curve 
show large correlation for size V (r2=0.735, p<0.0001). The 
loess point of inflection (value taken from the y axis) is 
approximately 22–24 dB. loess= locally estimated scatterplot 
smoothing.
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of 10 dB or higher, that is, when sufficient visual field was 
discernible. We found mean deviation to be higher for 
size III generally up to 20–25 dB at which level mean devi-
ation for size V was higher which likely reflects the greater 
extent of visual field seen with size V than size III. This 
effect disappeared for very poor visual fields, even with 
size V. Our study only included stages 3–4 advanced glau-
coma with cases where there was substantial visual field 
loss to the extent that perimetry with size III no longer 
provided adequate information to facilitate monitoring 
of the condition for progression/response to treatment. 
Changing to size V allowed us to further evaluate visual 
fields with more visual field information being obtained.
The standard loss variance provides a single global 
indicator value for the extent of localised visual field loss 
that is present. Our results indicate higher standard loss 
variance measures with size V likely due to greater visual 
field responses being obtained with the larger size target. 
Further, and not surprising, we found longer test dura-
tions for size V compared with size III and in keeping with 
other studies.22 This reflects the greater visual response to 
the larger size V target. Thus, the more targets than can 
be detected and responded to, the longer the test time 
will be.
We addressed a methodological issue with this paper. 
Many studies reporting visual field analysis present data 
from one eye: often the worst eye. We evaluated the distri-
bution of data for all eyes in this study as our primary 
analysis. We subsequently ran a sensitivity analysis of worst 
eyes only to determine where significance lies when only 
focussing on the worst eye and where the sample size is 
smaller. We found no differences in distribution for right 
versus left eyes or for worst versus better eyes except 
for mean deviation which showed more significance 
for primary analysis and which likely reflects the larger 
sample size for primary analysis (all eyes). Such evalua-
tion of distribution is essential if wishing to combine 
results from all eyes in reporting data. Clearly analysis and 
reporting of data is important in the context of the type 
of study. Reporting intervention outcomes often neces-
sitates a determination of independent effect. Hence 
reporting data from one eye per subject is often appro-
priate where the condition affects both eyes. However, in 
studies of assessment comparisons (such as this present 
study) the question being asked is about the ability of 
each assessment/test to detect the same defect and that 
question is as important for each eye individually (as two 
independent comparisons) as for the patients individually 
(as a single comparison). We have reported our methods 
and results in establishing the distribution of data and 
our subsequent decision to combine results versus solely 
presenting worst eye data only. As seen from our results 
across tables 1 and 2, values were highly comparable for 
all eyes versus worst eyes only.
Limitations
Our study is limited by a number of factors. We report 
visual field results but did not collect visual acuity or 
fundus imaging for this study. We also did not formally 
record patient preference for visual field testing with size 
III or V. Further, we did not evaluate test reliability by 
accounting for false positive and false negative responses, 
although excessive responses were exclusion criteria for 
our study. We do not believe these are major limiting 
factors as we considered this a pragmatic clinical study 
centred on evaluating the differing visual field results 
Table 2 Differences in visual field parameters for target size—worst eyes
G1, size III G1, size V Difference
Mean SD Mean SD Mean SD Paired T test Bonferroni correction
MS 6.31 5.57 12.24 7.67 −5.93 4.43 0.0001 0.0002
MD 20.72 5.63 20.00 7.59 0.72 4.39 0.072 0.144
SLV 5.73 2.34 7.67 2.70 −1.94 2.59 0.0001 *
DD 18.13 7.84 15.58 9.44 2.54 5.78 0.0001 *
MS Q1 4.80 5.38 9.92 8.57 −5.11 5.47 0.0001 *
MS Q2 7.00 7.52 13.64 9.61 −6.64 5.36 0.0001 *
MS Q3 5.73 5.85 11.26 8.74 −5.52 5.80 0.0001 *
MS Q4 7.49 7.44 13.86 10.06 −6.37 5.65 0.0001 *
MD Q1 21.88 5.42 21.75 8.46 0.12 5.42 0.801 *
MD Q2 20.34 7.57 19.08 9.60 1.27 5.34 0.01 *
MD Q3 20.85 5.93 20.42 8.62 0.43 5.73 0.407 *
MD Q4 19.85 7.46 18.86 9.99 0.99 5.64 0.053 *
Duration 3.31 1.07 6.36 1.37 −3.05 1.65 0.0001 *
Q1 (superior nasal field); Q2 inferior nasal field); Q3 (superior temporal field); Q4 (inferior temporal field).
*Not corrected as study not powered for these comparisons.
MS, mean sensitivity; MD, mean deviation; SLV, standard loss variance; DD, diffuse defect.
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obtained from size III and V stimuli. Hence, visual acuity 
and fundus imaging would not impact on our analysis. In 
future studies, we would wish to include patient feedback 
on preference for stimulus size as better patient engage-
ment with visual field assessment is important.
CONCLUSIONS
Use of size V versus III in standard automated perimetry 
for advanced stages 3–4 in glaucoma permits further 
visual field to be plotted in cases where the visual fields 
with size III no longer provides sufficient information 
to appropriately monitor the disease. Mean sensitivity, 
standard loss variance and test duration increased in 
accordance with the extra visual field responses obtained 
using size V. We do not infer that automated perimetry 
with size V is better than with size III. Size V is easier to 
detect and, thus, from a pragmatic clinical view, a switch 
from size III to V in patients with advanced disease was a 
logical alteration to the visual field assessment protocol. 
We recommend considering a change to size V stimulus 
for advanced glaucoma at stages 3–4 when, with size III, 
the mean sensitivity reaches 10 dB and/or mean devi-
ation reaches 18 dB, to facilitate continued assessment 
of visual fields as part of the clinical monitoring of the 
condition.
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Figure 3 Mean sensitivity and mean deviation 
comparisons—sensitivity analysis of worst eyes. (A) Mean 
sensitivity. straight line is the linear regression line; curved line 
is the loess regression curve. Comparisons generally show 
clustering where mean sensitivity is close to 0 dB, that is, 
worst visual field. There is a ‘floor’ effect with size III, yielding 
many zeros, while size V gives, for most, larger values. The 
linear regression line and loess regression curve show large 
correlation for size V (r2=0.678, p<0.0001). The loess point of 
inflection (value taken from the y axis) is approximately 3–5 
dB.(B) Mean deviation. Straight line is the linear regression 
line; curved line is the loess regression curve. The linear 
regression line and loess regression curve show large 
correlation for size V (r2=0.687, p<0.0001). The loess point of 
inflection (value taken from the y axis) is approximately 22–24 
dB. loess= locally estimated scatterplot smoothing.
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